GLOW peptide: what’s in the blend and what the research shows

  • By Reed Calder
  • Last reviewed Oct 29, 2026
  • 13 studies and FDA documents checked

In short

GLOW is a pre-mixed vial of three peptides: GHK-Cu, BPC-157 and TB-500, usually 50, 10 and 10 mg. No published study has tested the blend. Each ingredient has been studied on its own, mostly in cells and animals, and GHK-Cu’s human studies used creams and gels on the skin, not injections. None of the three is FDA-approved.

EvidenceCellAnimalHumanNo published study of the blend

GLOW is sold mainly for skin: firmness, collagen and the “glow” in its name. Most pages about it are written by clinics or sellers, and few cite a study. This page covers what each ingredient has actually been tested for, what the FDA said about each one in 2026, and what nobody knows yet.

What’s in a GLOW vial

A typical GLOW vial
Ingredient What it is Typical amount Best human evidence
GHK-Cu A copper-binding peptide found naturally in blood 50 mg Creams and a gel on the skin; no published injection studies
BPC-157 A 15-amino-acid peptide based on a stomach protein 10 mg Three small studies, 30 people, no control group; one more report gave it in a mix
TB-500 A lab-made seven-amino-acid piece of thymosin beta-4 10 mg One report of three patients, TB-500 in a mix; no control group

Amounts vary by seller. The 50, 10 and 10 mg split, sold as “GLOW 70” or a “glow stack,” was the most common on the listings we reviewed. That makes GHK-Cu about 71% of the vial.

KLOW is the same three peptides plus a fourth, KPV.

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. GLOW is a mix, so it has no CAS number of its own; each ingredient has one.

GLOW ingredient CAS numbers
Form CAS number Registry record
GHK-Cu (drug name prezatide copper) 89030-95-5 FDA GSRS
BPC-157 137525-51-0 FDA GSRS
TB-500 (Ac-LKKTETQ, 7 amino acids) 885340-08-9 FDA GSRS

Has the blend been studied?

No. We searched PubMed for studies combining these ingredients and found none that tested GLOW, or all three together. Reviews written for doctors in 2026 cover each ingredient separately (Mayfield et al., 2026; Mendias and Awan, 2026).

The closest thing: two of the ingredients in rats

One study has tested two blend ingredients together. In 32 rats with a repaired Achilles tendon, TB-500 made the tendon stronger and better organized, BPC-157 didn’t reach significance, and giving both added nothing over TB-500 alone (Biçer et al., 2026). It’s one small animal study, but it’s the only direct test of combining them, and more wasn’t better.

EvidenceCellAnimalHuman1 study, 8 rats per group

GHK-Cu: mostly creams on the skin

In cells grown in a dish, GHK-Cu increased the collagen that skin cells made (Maquart et al., 1988). In people, a GHK-Cu gel applied to diabetic foot ulcers closed more of the wound than a plain gel, a median of 98.5% against 60.8%, in a trial run with the gel’s developer (Mulder et al., 1994).

The facial results quoted on many pages, such as firmer skin and fewer fine lines in 12-week studies of 41 to 71 women, come from a review by GHK’s discoverer, whose listed affiliation is a skin-care company. The studies it cites for those results are a 2002 conference presentation, a university report and a book chapter, not peer-reviewed papers (Pickart et al., 2015).

The one randomized GHK-Cu skin trial we found in PubMed tested skin care after laser resurfacing. Blinded measurements found no difference in redness, wrinkles or overall skin quality. Patients using GHK-Cu rated their skin better (Miller et al., 2006; 13 patients).

EvidenceCellAnimalHumanHuman studies used creams and gels, not injections

BPC-157

BPC-157 has a large body of animal research. In people, a 2026 systematic review found three small studies, 30 people in all, none with a control group (Poolton et al., 2026).

EvidenceCellAnimalHuman3 uncontrolled studies

TB-500

No published study has given TB-500 to people, and the FDA’s 2026 review found no toxicity studies (FDA, 2026). Our TB-500 page covers its six cell and animal studies.

EvidenceCellAnimalHumanNo human studies

Three ingredients, each with thin human evidence on its own, and none on the combination.

The skin and before-and-after claims, checked

The skin claims made for GLOW come from GHK-Cu. Here is what they rest on.

  • Creams aren’t injections. Every human skin study of GHK-Cu we found applied it to the skin. We haven’t found a published study of injected GHK-Cu in people, and a 2026 review for sports doctors found no clinical data for its use in muscle and joint conditions (Mayfield et al., 2026).
  • The collagen finding is from cells. GHK-Cu raised collagen production in skin cells in a dish (Maquart et al., 1988). That shows a mechanism. It doesn’t show a visible change in a person.
  • Before-and-after photos aren’t studies. They have no comparison group, and lighting, angle and other treatments change how skin looks. In the laser trial, patients rated GHK-Cu skin better while blinded measurements found no difference (Miller et al., 2006).
  • BPC-157 and TB-500 have no skin studies in people. Their skin-related research is wound healing in animals.

Side effects and safety

  • No study has measured GLOW’s side effects. The side effects listed on clinic and seller pages, such as stinging where the needle goes in, come from customer reports, not trials.
  • Each ingredient raised FDA concerns. When the FDA reviewed requests to let pharmacies compound these peptides, it listed the concerns below (FDA, 2026).
FDA safety concerns, April 2026
Ingredient What the FDA flagged
GHK-Cu, injected Possible immune reactions from clumping and impurities; limited data in people
BPC-157 Possible immune reactions; impurity concerns; little or no safety information for the proposed routes of use
TB-500 Possible immune reactions from clumping and impurities; important safety information missing
  • Copper. Copper is roughly 15% of GHK-Cu’s weight, so the 50 mg in a typical vial carries several milligrams of it. We haven’t found a study of copper levels in people who inject GHK-Cu.
  • One vial, fixed ratio. In a pre-mixed vial, changing the amount of one ingredient changes all three. We haven’t found published data on how stable these peptides are mixed together.
  • What reviewers conclude. A 2026 review for sports medicine doctors found rigorous human safety data for these unapproved peptides scarce, with potential for serious harm (Mendias and Awan, 2026).

Legal and approval status

  • Not FDA-approved. Neither GLOW nor any of its ingredients is approved for any use.
  • GHK-Cu has no compounding route for injection. Requests to let pharmacies compound GHK-Cu were withdrawn in April 2026; in May one was restored for non-injectable use only. The FDA lists GHK-Cu “except for injectable routes” as under evaluation and plans to consult its advisory committee before the end of February 2027 (FDA, 2026).
  • Temporary HHS policy covers BPC-157 and TB-500, not GHK-Cu. Since October 28, 2026, licensed U.S. pharmacies may compound BPC-157 and TB-500 and three other peptides with a prescription while the FDA decides. GHK-Cu, the largest ingredient in GLOW, isn’t on that list, and the policy isn’t FDA approval (Reuters, 2026).
  • “Research use only” products aren’t approved for use in people.
  • Banned in sport. TB-500 is on the World Anti-Doping Agency’s prohibited list (FDA, 2026).

What to look for if you research it

We don’t name or link sellers. These checks come from the published analyses:

  • Every ingredient and its amount on the label. The blend name alone doesn’t tell you what’s inside, and vial sizes vary.
  • An identity test for each of the three peptides. A certificate of analysis for a blend should confirm each one by mass spectrometry, not give a single purity number for the whole vial.
  • Labels don’t always match contents. Anti-doping scientists found products sold online as TB-500 weren’t consistent with their labels (Delcourt et al., 2023).

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.

What’s still unknown

  • Whether GLOW does anything in people, for skin or for healing.
  • Whether combining the three adds anything. The only test of two of them together found no added benefit in rats.
  • What injected GHK-Cu does, and what repeated copper exposure from it does.
  • Whether the three peptides stay stable mixed in one vial.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention GLOW's ingredients. We recheck every month. Last checked Nov 13, 2026.

Flagged studies that mention GLOW's ingredients

Retracted, withdrawn and flagged studies
Study What it was about Status
Grubisic et al., 2025 Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats. Withdrawn · notice
Li et al., 2023 Deficiency of endothelial sirtuin1 in mice stimulates skeletal muscle insulin sensitivity by modifying the secretome. Retracted (2026) · notice
Zhang et al., 2021 Tβ4 ameliorates oxidative damage and apoptosis through ERK/MAPK and 5-HT1A signaling pathway in Aβ insulted SH-SY5Y cells. Withdrawn (2021) · notice
Bokor et al., 2018 Molecular Motions and Interactions in Aqueous Solutions of Thymosin-β4 , Stabilin C-Terminal Domain (CTD) and Their 1:1 Complex Studied by 1 H NMR Spectroscopy. Retracted (2020) · notice
Li et al., 2017 MiR-200a mediates protection of thymosin beta 4 in cardiac microvascular endothelial cells as a novel mechanism under hypoxia-reoxygenation injury. Retracted (2019) · notice
Lee et al., 2013 The role of thymosin beta 4 on odontogenic differentiation in human dental pulp cells. Retracted (2025) · notice
Smart et al., 2002 A differential screen for putative targets of the bHLH transcription factor Hand1 in cardiac morphogenesis. Retracted (2002) · notice

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Maquart et al., 1988 FEBS Lett No retraction or concern
Miller et al., 2006 Arch Facial Plast Surg No retraction or concern
Mulder et al., 1994 Wound Repair Regen No retraction or concern
Pickart et al., 2015 Biomed Res Int No retraction or concern
Delcourt et al., 2023 Drug Test Anal No retraction or concern
Mayfield et al., 2026 Am J Sports Med No retraction or concern
Mendias and Awan, 2026 Sports Med No retraction or concern
Biçer et al., 2026 Jt Dis Relat Surg No retraction or concern
Froum et al., 2026 Front Oral Health No retraction or concern
Poolton et al., 2026 Acta Orthop Belg No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

Does the GLOW peptide work?

No study has tested it, so nobody can say. Its ingredients have mostly cell and animal research. GHK-Cu’s human skin studies used creams, and the best-controlled one found no measurable difference (Miller et al., 2006).

What’s the difference between GLOW and KLOW?

KLOW is GLOW plus 10 mg of KPV, a small peptide studied for inflammation in mice. Neither blend has been studied. See the KLOW page for a side-by-side table.

Do peptides improve collagen?

GHK-Cu raised collagen production in cells in a dish (Maquart et al., 1988), and small cream studies reported firmer skin. We haven’t found a study showing that injected GHK-Cu, or GLOW, increases collagen in people.

Is a “glow stack” or GLOW 70 the same thing?

Yes. They are names sellers use for the same three-peptide mix. The 70 is the total in milligrams: 50 + 10 + 10.

What dose of GLOW do people use?

There’s no dose from a study. No study has given the blend to people. The only human report that included TB-500 gave three patients a mix of several drugs, with no comparison group (Froum et al., 2026). We don’t give dosing advice.

Is GLOW legal?

It isn’t FDA-approved. A temporary HHS policy lets pharmacies compound BPC-157 and TB-500 with a prescription, but not GHK-Cu, the largest ingredient. Products sold as “research use only” aren’t approved for use in people.

Sources

  1. Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. PubMed 3169264
  2. Mulder GD, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-69. PubMed 17147644
  3. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PubMed 26236730
  4. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. PubMed 16847171
  5. Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review. Acta Orthop Belg. 2026;92(3). PubMed 42885452
  6. Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats. Jt Dis Relat Surg. 2026;37(3):822-37. PubMed 42542926
  7. Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026;54(1):223-9. PubMed 41476424
  8. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-35. PubMed 41966639
  9. Delcourt V, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023;15(4):458-64. PubMed 36482504
  10. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
  11. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Updated May 14, 2026. FDA document
  12. U.S. Food and Drug Administration. Evaluation of TB-500-related bulk drug substances. Pharmacy Compounding Advisory Committee briefing document, July 23-24, 2026. FDA document
  13. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
  14. U.S. Food and Drug Administration. Global Substance Registration System: Prezatide copper (UNII 6BJQ43T1I9). GSRS
  15. U.S. Food and Drug Administration. Global Substance Registration System: BPC-157 (UNII 8ED8NXK95P). GSRS
  16. U.S. Food and Drug Administration. Global Substance Registration System: TB-500 (UNII QHK6Z47GTG). GSRS

Last reviewed Oct 29, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.